NewGenIvf Group Limited (NIVF) is a Bangkok-based, Nasdaq-listed holding company whose legacy business provides in vitro fertilization and assisted reproductive services across Thailand, Cambodia, Hong Kong and Kyrgyzstan. It has since expanded into UAE real estate development through NewGenProperty, digital-asset and decentralized-finance initiatives through NewGenDigital, and health and longevity products through NewGenSup, alongside a microfluidic cytometry platform held via its Nodexus subsidiary.
The stock was quoted at $0.0325 in Thursday's midday session, a decline of 80.94% from the previous completed session's close of $0.1705. The move was unambiguously to the downside. Shares opened at $0.042 and traded in a range of $0.0303 to $0.0435. The immediate reason cited by the market is the pricing of a $2.5 million underwritten equity offering at $0.035 per share, announced before the opening bell.
NewGenIvf priced a firm-commitment underwritten offering of 71,428,570 Class A ordinary shares, or pre-funded warrants in lieu thereof, at $0.035 per share — the pre-funded warrants priced at $0.03499 with an exercise price of $0.00001. Gross proceeds are expected to be approximately $2.5 million before fees, with Aegis Capital Corp. acting as sole book-running manager. The transaction is expected to close on or about Nov. 20, 2026, subject to customary conditions, and net proceeds are earmarked for general corporate purposes and working capital.
That offering price sat about 79% beneath the $0.1705 level where the stock last closed, which is why the shares repriced almost immediately to trade in the mid-$0.03s. The raise was executed under a Form F-3 shelf registration statement declared effective on Nov. 12, 2026.
The central problem for existing holders is scale. With a market capitalization of roughly $0.3 million before the announcement, the 71.4 million new shares represent an extraordinary expansion of the share count relative to the company's prior equity base, diluting existing holders far more than the modest $2.5 million in gross proceeds would suggest on its own.
This is not an isolated event. NewGenIvf raised $1.25 million at $0.07 per share in late September, and on Nov. 9 filed a mixed securities shelf allowing for up to $100 million in shares, warrants and debt. The company has also completed three reverse stock splits since September — 1-for-3, 1-for-4 and 1-for-8, the last effective Oct. 23. For a company that reported just $1.02 million of cash as of June 30, 2026 and a first-half net loss, each new raise reinforces the view that equity issuance is a recurring funding mechanism rather than a one-off event.
Participation was unusually heavy. More than 6.7 million shares traded by late morning against an average daily volume near 1.7 million, a pace of over four times normal turnover, which confirms that the repricing reflected genuine order flow rather than a thin print.
The broader tape was lower but nowhere near this magnitude: the S&P 500 proxy slipped about 0.86%, the Nasdaq-100 proxy about 0.72%, and small-cap shares about 1.42%. The divergence makes clear that the decline is idiosyncratic and tied to the financing, not to sector or macro sentiment. Technically, the stock opened far below every recent reference level, and the intraday low of $0.0303 briefly pierced the offering price itself, a sign that demand was thin even at the deal price. The shares remain far below their 20-day and 200-day moving averages and deep in penny-stock territory, well under Nasdaq's $1.00 minimum bid threshold.
The scale runs from 0, meaning no meaningful news and a price move that is routine for the stock, to 100, meaning transformative verified news combined with an extreme and rare move. This event scores 76 out of 100.
The verified news is material for a company of this size: a financing priced roughly 79% below the last sale that multiplies the share count many times over is a fundamental, highly dilutive development rather than a routine announcement. The price response was roughly 5.6 times the stock's average absolute daily move of about 14.5% across the prior 69 sessions, yet it was not unprecedented — one session in the last 60 was larger, a 133% rally on Sept. 30, and the shares fell 79% in a single session on Sept. 29. A strong catalyst and a large but not unique move combine to a high, not maximal, score.
The offering is scheduled to close on or about Nov. 20, at which point the enlarged share count becomes the base for all per-share metrics. Investors will be watching the post-deal share structure and whether the $2.5 million in proceeds meaningfully extends the company's runway given its cash burn. Formal interim results remain a focus, following the Nov. 16 business update that showed flat IVF and assisted-reproductive revenue for the six months ended June 30, 2026 and cited softer industry demand and the Thailand–Cambodia conflict's effect on patient travel.
On the regulatory front, maintaining compliance with Nasdaq's minimum bid price requirement is an ongoing overhang, particularly after three reverse splits in roughly two months. Operationally, milestones include China's NMPA registration work for the NX One platform, a non-binding collaboration agreement with Hainan Provincial Cancer Hospital, the agreement to acquire an additional 11% of PredicXion Group, and $4.71 million in deposits paid toward a Ras Al Khaimah land project for which no definitive sale and purchase agreement has been signed. Further issuance under the $100 million shelf is the principal risk to the share price.
Tickeron's Trending AI Robots page is a curated window into the platform's automated trading lineup. Tickeron offers hundreds of AI trading bots spanning thousands of tickers, but only the strongest performers under current market conditions earn a place in this featured section. Bots differ widely by strategy, timeframe, performance metrics and the symbols they trade, so the roster shifts as conditions change. Reviewing the current leaders is a practical way to see which approaches are working right now — visit the page to explore the live rankings.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
I’m a trader and independent researcher. My interest lies at the intersection of financial markets, algorithms, and capital management. I develop data-driven tools and strategies and study algorithmic approaches to market analysis. I help turn complex market data into clear insights and practical systems. I believe technology should support, not replace, investment thinking
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where NIVF declined for three days, in 237 of 241 cases, the price declined further within the following month. The odds of a continued downward trend are 90%.
The Aroon Indicator for NIVF entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 22 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 37 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.041) is normal, around the industry mean (204.532). P/E Ratio (0.000) is within average values for comparable stocks, (21.572). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.498). Dividend Yield (0.000) settles around the average of (0.153) among similar stocks. P/S Ratio (0.005) is also within normal values, averaging (2.688).
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 99 (best 1 - 100 worst), indicating slightly worse than average price growth. NIVF’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NIVF’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry HospitalNursingManagement